Cadrenal Therapeutics, Inc.
Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
About
CEO
Mr. Quang X. Pham
Employees
4
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
822 A1A North, Ponte Vedra, FL 32082, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 8, 2024 | -1.93 | -2.18 | -0.25 | 12.95% |
| Aug 8, 2024 | -0.08 | -0.15 | -0.07 | 87.50% |
| May 9, 2024 | -0.07 | -0.10 | -0.03 | 42.86% |
| Mar 11, 2024 | -0.08 | -0.05 | 0.03 | -37.50% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 2 |
| Average estimate | — | -2.15 | — | -4.27 |
| Low estimate | — | -2.15 | — | -5.76 |
| High estimate | — | -2.15 | — | -2.78 |
| Last year EPS | — | -1.50 | — | -7.80 |
[stock_revenue_estimate]
Growth estimates
Current qtr
0.530%
Next qtr. (Mar 2025)
-43.330%
Current year
5.260%
Next year (Dec 2025)
45.220%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 4.08M |
| Selling general and admin | 3.55M |
| Other operating expenses | — |
| Operating income | -7.63M |
| Non operating interest income | |
| Income | 249,092 |
| Expense | 17,101 |
| Other income expense | -956,234 |
| Pretax income | -8.36M |
| Tax provision | — |
| Net income | -8.36M |
| Basic EPS | -9.30 |
| Diluted EPS | -9.30 |
| Basic average shares | 899,465 |
| Diluted average shares | 899,465 |
| EBITDA | -7.38M |
| Net income from continuing op. | -8.36M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total assets | 8.52M | 778,174 |
| Current assets | ||
| Cash | — | 32,586 |
| Cash equivalents | — | — |
| Cash and cash equivalents | 8.40M | 32,586 |
| Other short term investments | — | — |
| Accounts receivable | — | — |
| Other receivables | — | — |
| Inventory | — | — |
| Prepaid assets | 89,673 | 22,715 |
| Restricted cash | — | — |
| Assets held for sale | — | — |
| Hedging assets | — | — |
| Other current assets | — | — |
| Non current assets | ||
| Properties | 23,285 | 44,591 |
| Land and improvements | — | — |
| Machinery furniture equipment | — | — |
| Construction in progress | — | — |
| Leases | — | — |
| Accumulated depreciation | — | — |
| Goodwill | — | — |
| Investment properties | — | — |
| Financial assets | — | — |
| Intangible assets | — | — |
| Investments and advances | — | — |
| Other non current assets | 3,792 | 5,987 |
| Total liabilities | 826,875 | 6.33M |
| Current liabilities | ||
| Accounts payable | 167,319 | 404,897 |
| Accrued expenses | 42,075 | 258,274 |
| Short term debt | 21,350 | 66,016 |
| Deferred revenue | — | — |
| Tax payable | — | — |
| Pensions | 596,131 | 605,290 |
| Other current liabilities | — | — |
| Non current liabilities | ||
| Long term debt | — | 574,690 |
| Provision for risks and charges | — | — |
| Deferred liabilities | — | — |
| Derivative product liabilities | — | 4.38M |
| Other non current liabilities | — | — |
| Shareholders equity | ||
| Common stock | 13,022 | 8,194 |
| Retained earnings | -15.07M | -6.71M |
| Other shareholders equity | — | — |
| Total shareholders equity | 7.69M | -5.55M |
| Additional paid in capital | 22.75M | 1.15M |
| Treasury stock | — | — |
| Minority interest | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -8.36M |
| Depreciation | 1,980 |
| Deferred Taxes | — |
| Stock-Based Compensation | 710,381 |
| Other Non-Cash Items | 3.01M |
| Accounts Receivable | — |
| Accounts Payable | -237,578 |
| Other Assets & Liabilities | 674,490 |
| Operating Cash Flow | -4.19M |
| Investing Activities | |
| Capital Expenditures | -3,254 |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -3,254 |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | -250,000 |
| Other Financing Charges | — |
| Financing Cash Flow | 11.40M |
| Other Cash Details | |
| End Cash Position | 8.40M |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -3.53M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 3,195 | 61,024 | 0.18% |
| Fidelity Total Market Index Fund | Nov 30, 2024 | 1,109 | 21,181 | 0.06% |
| Fidelity Series Total Market Index Fund | Nov 30, 2024 | 777 | 14,840 | 0.04% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 60 | 1,146 | 0.00% |
Article
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25 years of leadership in the cardiovascular f.
Feb 6, 2025
Article
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will present at the 2025 BIO CEO & Investor Conference taking place at The New York Marriott Marquis on February 10-11, 2025. Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics, Inc., will present an overview of the company and updates on the.
Feb 5, 2025
Article
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior.
Jan 9, 2025
